Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA. et al. Osteosarcoma. Nat Rev Dis Prim. 2022;8:77

Article  PubMed  Google Scholar 

Yan GN, Lv YF, Guo QN. Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. Cancer Lett. 2016;370:268–74.

Article  CAS  PubMed  Google Scholar 

Cortini M, Avnet S, Baldini N. Mesenchymal stroma: role in osteosarcoma progression. Cancer Lett. 2017;405:90–9.

Article  CAS  PubMed  Google Scholar 

Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O, 3rd. et al. Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children’s Cancer Group, pediatric oncology group, and children’s oncology group: learning from the past to move forward. J Clin Oncol. 2016;34:3031–8.

Article  PubMed  PubMed Central  Google Scholar 

Whelan JS, Davis LE. Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol. 2018;36:188–93.

Article  CAS  PubMed  Google Scholar 

Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D. et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children’s Oncology Group. J Clin Oncol : J Am Soc Clin Oncol. 2008;26:633–8.

Article  CAS  Google Scholar 

Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD. et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17:1396–408.

Article  PubMed  PubMed Central  Google Scholar 

Gaspar N, Occean BV, Pacquement H, Bompas E, Bouvier C, Brisse HJ. et al. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. Eur J cancer (Oxf, Engl : 1990). 2018;88:57–66.

Article  CAS  Google Scholar 

Huang H, Lu Q, Yuan X, Zhang P, Ye C, Wei M. et al. Andrographolide inhibits the growth of human osteosarcoma cells by suppressing Wnt/β-catenin, PI3K/AKT and NF-κB signaling pathways. Chem-Biol Interact. 2022;365:110068

Article  CAS  PubMed  Google Scholar 

Alizadehnohi M, Nabiuni M, Nazari Z, Safaeinejad Z, Irian S. The synergistic cytotoxic effect of cisplatin and honey bee venom on human ovarian cancer cell line A2780cp. J Venom Res. 2012;3:22–7.

CAS  PubMed  PubMed Central  Google Scholar 

Lu Q, Huang H, Wang X, Luo L, Xia H, Zhang L. et al. Echinatin inhibits the growth and metastasis of human osteosarcoma cells through Wnt/β-catenin and p38 signaling pathways. Pharmacol Res. 2023;191:106760

Article  CAS  PubMed  Google Scholar 

Ruibin J, Bo J, Danying W, Jianguo F, Linhui G. Cardamonin induces G2/M phase arrest and apoptosis through inhibition of NF-κB and mTOR pathways in ovarian cancer. Aging. 2020;12:25730–43.

Article  PubMed  PubMed Central  Google Scholar 

Liao NC, Shih YL, Ho MT, Lu TJ, Lee CH, Peng SF. et al. Cardamonin induces immune responses and enhances survival rate in WEHI-3 cell-generated mouse leukemia in vivo. Environ Toxicol. 2020;35:457–67.

Article  CAS  PubMed  Google Scholar 

Cardenas Garza GR, Elizondo Luevano JH, Bazaldua Rodriguez AF, Chavez Montes A, Perez Hernandez RA, Martinez Delgado AJ, et al. Benefits of cardamom (Elettaria cardamomum (L.) Maton) and turmeric (Curcuma longa L.) extracts for their applications as natural anti-inflammatory adjuvants. Plants. 2021;10:1908–25.

Zhang L, Yang C, Huang Y, Huang H, Yuan X, Zhang P. et al. Cardamonin inhibits the growth of human osteosarcoma cells through activating P38 and JNK signaling pathway. Biomed Pharmacother Biomed Pharmacother. 2021;134:111155

Article  CAS  PubMed  Google Scholar 

Ianevski A, Lahtela J, Javarappa KK, Sergeev P, Ghimire BR, Gautam P, et al. Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Sci Adv. 2021;7:1126.

Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A. et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202–13.

Article  CAS  PubMed  Google Scholar 

Gfeller D, Michielin O, Zoete V. Shaping the interaction landscape of bioactive molecules. Bioinformatics. 2013;29:3073–9.

Article  CAS  PubMed  Google Scholar 

Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X. et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45:W356–w60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davis AP, Murphy CG, Saraceni-Richards CA, Rosenstein MC, Wiegers TC, Mattingly CJ. Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical-gene-disease networks. Nucleic Acids Res. 2009;37:D786–92.

Article  CAS  PubMed  Google Scholar 

Pichler K, Warner K, Magrane M. SPIN: submitting sequences determined at protein level to UniProt. Curr Protoc Bioinform. 2018;62:e52

Article  Google Scholar 

Safran M, Solomon I, Shmueli O, Lapidot M, Shen-Orr S, Adato A. et al. GeneCards 2002: towards a complete, object-oriented, human gene compendium. Bioinformatics. 2002;18:1542–3.

Article  CAS  PubMed  Google Scholar 

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13.

Article  CAS  PubMed  Google Scholar 

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18:744–57.

Article  CAS  PubMed  Google Scholar 

Lawrence JC, Lin TA, McMahon LP, Choi KM. Modulation of the protein kinase activity of mTOR. Curr Top Microbiol Immunol. 2004;279:199–213.

CAS  PubMed  Google Scholar 

Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu J, Zou H, Yu W, Huang Y, Liu B, Li T. et al. Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells. Cancer Cell Int. 2019;19:195

Article  PubMed  PubMed Central  Google Scholar 

Baehrecke EH. Autophagy: Dual roles in life and death?. Nat Rev Mol Cell Biol. 2005;6:505–10.

Article  CAS  PubMed  Google Scholar 

Wright TJ, McKee C, Birch-Machin MA, Ellis R, Armstrong JL, Lovat PE. Increasing the therapeutic efficacy of docetaxel for cutaneous squamous cell carcinoma through the combined inhibition of phosphatidylinositol 3-kinase/AKT signalling and autophagy. Clin Exp Dermatol. 2013;38:421–3.

Article  CAS  PubMed  Google Scholar 

Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3:1351–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wagner JM, Karnitz LM. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharm. 2009;76:208–14.

Article